Insulin-like growth factor receptor type I as a target for cancer therapy (Q37773265)

22 August 2017

1 reference

title

Insulin-like growth factor receptor type I as a target for cancer therapy (English)

1 reference

22 August 2017

Liliane Goetsch

1

1 reference

PubMed ID

20635945

22 August 2017

Nathalie Corvaïa

series ordinal

2

1 reference

22 August 2017

1 March 2009

1 reference

22 August 2017

1 reference

22 August 2017

1

1 reference

22 August 2017

2

1 reference

22 August 2017

265-279

1 reference

Normal growth and development in the absence of hepatic insulin-like growth factor I

22 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

The two mannose 6-phosphate binding sites of the insulin-like growth factor-II/mannose 6-phosphate receptor display different ligand binding properties

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Loss of insulin-like growth factor II receptor expression promotes growth in cancer by increasing intracellular signaling from both IGF-I and insulin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Immunological relationships between receptors for insulin and insulin-like growth factor I. Evidence for structural heterogeneity of insulin-like growth factor I receptors involving hybrids with insulin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Hybrid and atypical insulin/insulin-like growth factor I receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Signaling differences from the A and B isoforms of the insulin receptor (IR) in 32D cells in the presence or absence of IR substrate-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Structure and autoregulation of the insulin-like growth factor 1 receptor kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

The role of the IGF system in cancer growth and metastasis: overview and recent insights

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Specificity in ligand binding and intracellular signalling by insulin and insulin-like growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Insulin/IGF signalling in neurogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

The IGF‐1 receptor in cancer biology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Activation of the insulin-like growth factor-I receptor inhibits tumor necrosis factor-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Cadherin switch in tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

The role of the IGF-I receptor in the regulation of matrix metalloproteinases, tumor invasion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

IGF-1 induced vascular endothelial growth factor secretion in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Increased apoptosis and decreased proliferation of colorectal cancer cells using insulin-like growth factor binding protein-4 gene delivered locally by gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Structural biology of insulin and IGF1 receptors: implications for drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Biochemical and structural characterization of a novel class of inhibitors of the type 1 insulin-like growth factor and insulin receptor kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

IGF-1R tyrosine kinase expression and dependency in clones of IGF-1R knockout cells (R-).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Inhibitors of ABL and the ABL-T315I mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Insulin-like growth factor-I receptor signaling blockade combined with radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Substrate-bound insulin-like growth factor (IGF)-I-IGF binding protein-vitronectin-stimulated breast cell migration is enhanced by coactivation of the phosphatidylinositide 3-Kinase/AKT pathway by alphav-integrins and the IGF-I receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Insulin-like growth factor-I receptor, E-cadherin and alpha v integrin form a dynamic complex under the control of alpha-catenin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Circulating concentrations of insulin-like growth factor I and risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F1750743X.1.2.265

21 January 2018

Identifiers

DOI

10.2217/1750743X.1.2.265

1 reference

22 August 2017

1 reference

PubMed ID

20635945